DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE

FOOD AND DRUG ADMINISTRATION

APPLICATION FOR LICENSE FOR THE MANUFACTURE OF **ALLERGENIC PRODUCTS**

Form Approved: OMB No. 0910-0124. Expiration Date: November 31, 2001. See Page 5 For OMB Statement.

DATE SUBMITTED

NOTE: This report is mandated by Section 351 of the Public Health Service Act, the Federal Food, Drug and Cosmetic Act, Section 502 and Title 21 CFR Part 600. No license may be granted unless this completed application form has been received.

GENERAL INSTRUCTIONS

Type or print legibly in ink. Complete all items. Items which are not applicable enter "NA". If more space is needed for any item, continue on an 8 1/2 X 11 sheet, reference the entry by item number, and attach. Allow 1 inch top margin for filing purposes. Submit the original and yellow copy of

I. GENERAL INFORMATION 1. NAME OF THE FINAL PRODUCT FOR WHICH APPLICATION FOR LICENSE IS BEING MADE	Check One: NEW APPLICATION REVISED APPLICATION ELEPHONE NO. (Include area code)
	NEW APPLICATION□ REVISED APPLICATION
	ELEPHONE NO. (Include area code)
3. COMPLETE ADDRESS(ES) OF LOCATION(S) WHERE PRODUCT IS MANUFACTURED	
II. SOURCE MATERIALS	
4. NAME AND ADDRESS OF EACH SUPPLIER OF SOURCE MATERIAL, e.g., POLLEN, FOOD, MOLDS, E	ETC.
5. a. LICENSED MANUFACTURER INSPECTS SUPPLIER(S) OF SOURCE MATERIALS? b. RECORDS MAINTAINED? YES NO	NO
6. DESCRIBE METHOD OF OBTAINING SOURCE MATERIAL, INCLUDING THE PROPAGATION OF MOL	DS, IF APPLICABLE

7. a. HOW IS PURITY AND IDEN	ITITY OF SOURCE MA	TERIAL ESTABLISHED?			
h IS A WIDITTEN CERTIFICAT	TION DECEIVED EDON	A SLIDDLIED OF EVEN SHIDE	MENT OF SOURCE MATERIAL 2		
b. 13 A WRITTEN CERTIFICA	TION RECEIVED FROM	1 SUPPLIER OF EACH SHIFT	MENT OF SOURCE MATERIAL? YES NO		
III. EXTRACTION AND PREPARATION OF FINAL PRODUCT					
			URCE MATERIALS, AND CONDITIONS UNDER WHICH	н	
THE MATERIAL IS STORED.	TRECEIL L'AND L'RIOI	CIGEXINACTING THE SOC	ONCE MATERIALS, AND CONDITIONS UNDER WINO		
THE MICHELLIA CONTEST.					
9. METHOD OF EXTRACTION IN I	DETAIL, INCLUDING AT	WHAT TEMPERATURE AND	D TIME REQUIRED FOR EXTRACTION		
10. HOW IS EXTRACT STANDARI	DIZED?				
IV.		PRESERVATIVE			
11. KIND	AMOUNT	WHEN ADDED	ACCEPTABLE RANGE THROUGHOUT DATING PERI	IOD	
11. Kilyb	7111100111	WHEN ABBEB	THOSE THE ENTROPE THROUGHOUT BRITING FERE	100	
	L				
12. IN WHAT STRENGTHS AND F	ORMS IS THE PRODUC	ST MARKETED?			

FORM FDA 3213 (11/98) PAGE 2 OF 5

13.	DESCRIBE PREPARATION OF FINAL PRODUCT. INCLUDE DESCRIPTION OF ANY DILUENTS USED AND THE STERILE FILTRATION
	PROCEDURE
14.	HOW ARE THE CONTAINERS AND STOPPERS TREATED AND STERILIZED? INCLUDE WRITTEN SPECIFICATIONS FOR CONTAINERS AND CLOSURES
	AND CLOSURES
15.	HOW ARE THE CONTAINERS FILLED? AND UNDER WHAT PRECAUTIONS? INCLUDE INFORMATION ON SIZE AND TYPE OF ANY
	FILTERS USED. DESCRIBE HOW FILLING PROCEDURE IS VALIDATED
٧.	LABORATORY TESTING
16.	DESCRIBE STERILITY TESTS (bulk or stock concentrate and final containers)
17.	DESCRIBE GENERAL SAFETY TEST
	SECONDE CENTENTE ON ETT TECT
I	

FORM FDA 3213 (11/98) PAGE 3 OF 5

18. DESCRIBE POTENCY TESTS PERFORMED	
19. DESCRIBE IDENTITY TEST USED	
20. WHAT OTHER TESTS ARE MADE? DESCRIBE IN DETAIL, INCLUDING IF TEST IS PERFORMED ON BULK OR FINAL CONTAINER	
, , , , , , , , , , , , , , , , , , , ,	
21. a. HOW IS THE DATE OF MANUFACTURE OF PRODUCT ESTABLISHED?	
21. a. HOW IS THE DATE OF MANOFACTURE OF PRODUCT ESTABLISHED?	
b. WHAT IS THE EXPIRATION DATE OF THE PRODUCT AND HOW IS IT CALCULATED?	
22. HOW IS THE PRODUCT FOR MARKETING STORED AND AT WHAT TEMPERATURE:	
22. How to the thought for white process the first electrone.	
23. a. WHEN IS THE DATE PLACED ON THE FINAL CONTAINERS?	
23. a. WHEN IS THE DATE PLACED ON THE FINAL CONTAINERS?	
23. a. WHEN IS THE DATE PLACED ON THE FINAL CONTAINERS?	
23. a. WHEN IS THE DATE PLACED ON THE FINAL CONTAINERS?	
23. a. WHEN IS THE DATE PLACED ON THE FINAL CONTAINERS?	
23. a. WHEN IS THE DATE PLACED ON THE FINAL CONTAINERS? b. IF FINAL PRODUCT IS FREEZE-DRIED, WHAT EXPIRATION DATE IS ASSIGNED TO THE RECONSTITUTED PRODUCT?	

FORM FDA 3213 (11/98) PAGE 4 OF 5

b	 Printer's proofs of all labels, including the direction of package. Use "Transmittal of Labels and Circulars," 	circular, together with a prototype of a cor	nplete "mock-up"
С	c. Samples of protocols of manufacturer's tests of the	product, including identification of the stage	ge(s) of
	manufacture represented by the sample(s) submitted. Clinical evidence of safety, potency, and effectivene		reculte from all
u	pertinent studies contained in IND filing.	ss of the product, including summanes of	results iron air
е	 Stability data to assure the safety, purity and potent period. 	ey of the final product throughout the requ	ested dating
f.	. Environmental impact analysis report as required by	21 CFR, Part 601.2.	
25. C	OMMENTS		
26.		SPONSIBLE FOR THE PRODUCTION A	
26.	NAMES AND TITLES OF EXPERTS RE	SPONSIBLE FOR THE PRODUCTION A	AND TESTING OF PRODUCT SIGNATURE
26.			
26.			
26.			
26.			
26.			
26.			
26.	I certify that all statements made in the ability. I am familiar with the pertinent	TYPED NAME	SIGNATURE best of my knowledge and gulations, and am aware of
	I certify that all statements made in the ability. I am familiar with the pertinent my responsibilities described therein.	CERTIFICATION is application are true and correct to the Sections of Title 21, Code of Federal Rev	SIGNATURE best of my knowledge and gulations, and am aware of
	I certify that all statements made in the ability. I am familiar with the pertinent my responsibilities described therein. Code, Title 18, Section 1001.	CERTIFICATION is application are true and correct to the Sections of Title 21, Code of Federal Regulation are true and correct to the Sections of Title 21, Code of Federal Regulation (MARNING: A willfully false certification)	best of my knowledge and gulations, and am aware of is a criminal offense. U.S.

A federal agency may not conduct or sponsor and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Public reporting burden for this collection of information is estimated to average 12 hours per response, including time for reviewing instructions, searching existing data sources, gathering and maintaining the necessary data, and completing and reviewing the collection of information. Send comments regarding the burden estimate or any other aspect of this collection of information to:

DHHS/PHS/FDA/Director Center for Biologic Evaluation and Research (0910-0124) 1401 Rockville Pike (HFM-370) Rockville, MD 20852-1448

FORM FDA 3213 (11/98) PAGE 5 OF 5